At the 2012 European
- ECCO 2013: Is ODM-201 too late to the prostate cancer party?
- JNJ acquisition of Aragon ARN-509 deals a blow to Medivation
- What is the potential for galeterone in advanced prostate cancer?
- ASCO GU 2013 Prostate Cancer Preview #GU13
- Will dasatinib be effective in prostate cancer?
- ESMO 2012: TH-302 Pancreatic Cancer Survival Data Fails to Impress
- ESMO 2012: ODM-201 a new generation antiandrogen for advanced prostate cancer
- ASCO 2012 What is the Optimal Sequencing of Advanced Prostate Cancer Drugs?
- AACR 2012: Future is combinations of novel cancer agents
- AACR 2012: AZD3514 a new prostate cancer drug to watch